Cytokinetics
CYTK
430 hedge funds and large institutions have $8.86B invested in Cytokinetics in 2025 Q4 according to their latest regulatory filings, with 105 funds opening new positions, 143 increasing their positions, 134 reducing their positions, and 47 closing their positions.
306% more call options, than puts
Call options by funds: $477M | Put options by funds: $118M
123% more first-time investments, than exits
New positions opened: 105 | Existing positions closed: 47
14% more capital invested
Capital invested by funds: $7.75B → $8.86B (+$1.12B)
13% more funds holding
Funds holding: 380 → 430 (+50)
7% more repeat investments, than reductions
Existing positions increased: 143 | Existing positions reduced: 134
3.72% less ownership
Funds ownership: 117.77% → 114.05% (-3.7%)
6% less funds holding in top 10
Funds holding in top 10: 16 → 15 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$54.1M |
| 2 |
Goldman Sachs
New York
|
+$45.8M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$32.9M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$32.9M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$28.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$84.9M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$59.9M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$41.8M |
| 4 |
VPC
Vestal Point Capital
New York
|
-$39.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$29.3M |
CYTK Hedge Fund Activity: Q4 2025 in Review
430 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q4 2025, worth a combined $8.86B — up 14% from $7.75B a quarter earlier.
Buyers outnumbered sellers: 105 funds opened new CYTK positions and 47 closed out — a net gain of 58 holders — while 143 added to existing stakes and 134 trimmed.
The largest buyer was BlackRock, adding an estimated $54.1M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $84.9M.
- 430 institutional investors held Cytokinetics (CYTK) as of Q4 2025, up from 380 in Q3 2025.
- Funds reported $8.86B of Cytokinetics stock for Q4 2025, up 14% quarter-over-quarter.
- 105 funds opened new Cytokinetics positions in Q4 2025 and 47 closed out, a net change of +58 holders.
- The largest Cytokinetics buyer in Q4 2025 was BlackRock, an estimated $54.1M added.
- The largest Cytokinetics seller in Q4 2025 was T. Rowe Price Investment Management, an estimated $84.9M sold.
Based on aggregated 13F filings for Q4 2025.